Effects of Talampanel on Patients With Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and effectiveness of the study drug,
Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a
result of treatment to Parkinson's disease.
It is not clear why people with Parkinson's disease develop involuntary movements
(dyskinesias) but studies show that blocking receptors in the brain for a chemical called
glutamate decreases these movements. Talampanel is a drug which blocks these receptors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries